Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9305472 | 0.78 | APP (0.46) | PSMB8PDPK1 | |
| SCHEMBL2748587 | 0.76 | ALDH1A1 (0.35) | PSMB8HSP90AA1HSP90AB1 | |
| SCHEMBL2749435 | 0.76 | PSMB8 (0.56) | PSMB8AKR1B1HSP90AA1HSP90AB1 | |
| SCHEMBL2748327 | 0.76 | PSMB8 (0.36) | PSMB8AKR1B1HSP90AA1HSP90AB1 | |
| SCHEMBL660041 | 0.76 | PSMB8 (0.40) | BACE1PSMB8AKR1B1HSP90AA1HSP90AB1 | |
| SCHEMBL25156042 | 0.76 | RAB9A (0.42) | BACE1PSMB8AKR1B1HSP90AA1HSP90AB1 | |
| SCHEMBL1619718 | 0.76 | ASH1L (0.44) | BACE1HSP90AA1HSP90AB1PDPK1 | |
| SCHEMBL2749649 | 0.76 | BACE1 (0.36) | BACE1PSMB8AKR1B1HSP90AA1HSP90AB1 | |
| SCHEMBL9305633 | 0.73 | CA2 (0.38) | PSMB8 | |
| SCHEMBL2748734 | 0.73 | NQO2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705294-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | Aurigene Oncology Limited (IN) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024228132-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-11-07 | — | — | WO | disclosed |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | Wu, Xiao Hua (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | Wu, Xiao Hua (US) | 2019-03-05 | — | — | US | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| CN-101505762-A | Orally active purinyl inhibitors of heat shock protein 90 | CONFORMA THERAPEUTICS CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-5347008-A | Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents | CIBA-GEIGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| US-5152929-A | Corrosion inhibitors for water systems | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0161220-B1 | PROCESS FOR THE PREPARATION OF BETA-(BENZOTHIAZOLYLTHIO) AND BETA (BENZIMIDAZOLYLTHIO)CARBOXYLIC-ACID DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-08-14 | — | — | EP | disclosed |
| EP-0129506-B1 | HETEROCYCLICALLY SUBSTITUTED THIO(CYCLO)ALKANE POLYCARBOXYLIC ACIDS | CIBA-GEIGY AG (CH) | 1991-03-06 | — | — | EP | disclosed |
| US-4652653-A | Process for the preparation of β-(benzothiazolylthio)- and β-(benzimidazolylthio)-carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1987-03-24 | — | — | US | disclosed |
| US-4612378-A | Process for the preparation of β-(benzothiazolylthio)- and β-(benzimidazolylthio-carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0161220-A2 | Process for the preparation of beta-(benzothiazolylthio) and beta (benzimidazolylthio)carboxylic-acid derivatives | CIBA-GEIGY AG (CH) | 1985-11-13 | — | — | EP | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
| EP-0126030-A2 | Process for the preparation of beta-(benzothiazolylthio) and beta-(benzimidazolylthio) carboxylic acids | CIBA-GEIGY AG (CH) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | BACE1 3537/4885PSMB8 1513/4885AKR1B1 2309/4885 |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | BACE1 828/4885PSMB8 2973/4885AKR1B1 176/4885 |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | MAN2A1, MAN1B1, ALG1 | BACE1 2354/4885PSMB8 2737/4885AKR1B1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.